[go: up one dir, main page]

MA29378B1 - Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer - Google Patents

Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer

Info

Publication number
MA29378B1
MA29378B1 MA30267A MA30267A MA29378B1 MA 29378 B1 MA29378 B1 MA 29378B1 MA 30267 A MA30267 A MA 30267A MA 30267 A MA30267 A MA 30267A MA 29378 B1 MA29378 B1 MA 29378B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
pharmaceutical composition
diphenyluree
carboxyaryl
Prior art date
Application number
MA30267A
Other languages
English (en)
Inventor
Fritz Schueckler
Axel Wollenschlaeger
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36507604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29378(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA29378B1 publication Critical patent/MA29378B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE QUI COMPREND LE COMPOSÉ DE LA FORMULE (I) À UNE CONCENTRATION ÉLEVÉE ET AU MOINS UN EXCIPIENT PHARMACEUTIQUEMENT ACCEPTABLE, L'UTILISATION DE LA COMPOSITION POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES, TELLES QUE LE CANCER, SOIT COMME SEUL AGENT OU EN COMBINAISON AVEC D¿AUTRES THÉRAPIES ANTICANCÉREUSES, AINSI QUE LE PROCÉDÉ DE PRÉPARATION DE LADITE COMPOSITION.
MA30267A 2005-03-07 2007-10-02 Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer MA29378B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65882705P 2005-03-07 2005-03-07

Publications (1)

Publication Number Publication Date
MA29378B1 true MA29378B1 (fr) 2008-04-01

Family

ID=36507604

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30267A MA29378B1 (fr) 2005-03-07 2007-10-02 Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer

Country Status (38)

Country Link
US (2) US9737488B2 (fr)
EP (1) EP1868579B1 (fr)
JP (1) JP5304241B2 (fr)
KR (1) KR101335932B1 (fr)
CN (2) CN101132779B (fr)
AR (1) AR054234A1 (fr)
AT (1) ATE482693T1 (fr)
AU (1) AU2006222365B2 (fr)
BR (1) BRPI0608840B8 (fr)
CA (1) CA2601955C (fr)
CR (1) CR9348A (fr)
CU (1) CU23821A3 (fr)
CY (1) CY1111065T1 (fr)
DE (1) DE602006017188D1 (fr)
DK (1) DK1868579T3 (fr)
DO (1) DOP2006000057A (fr)
ES (1) ES2351612T3 (fr)
GT (1) GT200600096A (fr)
HK (2) HK1118019A1 (fr)
HN (1) HN2006009702A (fr)
HR (1) HRP20100674T1 (fr)
IL (1) IL185517A (fr)
MA (1) MA29378B1 (fr)
MX (1) MX2007010856A (fr)
MY (1) MY162319A (fr)
NO (1) NO343834B1 (fr)
NZ (1) NZ561178A (fr)
PE (1) PE20061345A1 (fr)
PL (1) PL1868579T3 (fr)
PT (1) PT1868579E (fr)
SG (1) SG160364A1 (fr)
SI (1) SI1868579T1 (fr)
TN (1) TNSN07341A1 (fr)
TW (1) TWI324928B (fr)
UA (1) UA93673C2 (fr)
UY (1) UY29410A1 (fr)
WO (1) WO2006094626A1 (fr)
ZA (1) ZA200707638B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
BRPI0515946A (pt) 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
DK1868579T3 (da) 2005-03-07 2011-01-10 Bayer Schering Pharma Ag Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
CA2627875A1 (fr) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Diaryle-urees et combinaisons
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2675980C (fr) 2007-01-19 2016-06-21 Bayer Healthcare Llc Utilisation de dast dans le traitement des cancers a resistance acquise a des inhibiteurs de kit
WO2009106825A1 (fr) * 2008-02-27 2009-09-03 Cipla Limited Polymorphes de sorafénib et leurs sels
ES2893785T3 (es) 2008-05-15 2022-02-10 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
WO2010142678A2 (fr) * 2009-06-12 2010-12-16 Ratiopharm Gmbh Polymorphes de 4-[4-[[4-chloro-3-(trifluorométhyl)phényl]carbamoylamino]phénoxy]-n-méthyl-pyridine-2-carboxamide
US8618305B2 (en) 2010-01-29 2013-12-31 Ranbaxy Laboratories Limited Sorafenib dimethyl sulphoxide solvate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
WO2012041987A1 (fr) 2010-10-01 2012-04-05 Bayer Pharma Aktiengesellschaft Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
EP2559431A1 (fr) 2011-08-17 2013-02-20 Ratiopharm GmbH Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide
EP2806860B1 (fr) 2012-01-23 2023-04-19 Sandoz AG Composition pharmaceutique contenant du tosylate sorafenib cristallin
CN104736178A (zh) * 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
EP3193877A4 (fr) 2014-08-07 2018-04-04 Pharmacyclics LLC Nouvelles formulations d'un inhibiteur de la tyrosine kinase de bruton
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3294951B1 (fr) * 2015-05-14 2021-06-23 DuPont Nutrition USA, Inc. Procédé de fabrication de cellulose microcristalline blanchie
WO2017159585A1 (fr) * 2016-03-14 2017-09-21 参天製薬株式会社 Agent antiseptique contenant de la méglumine ou un sel correspondant
CN106344530B (zh) * 2016-09-30 2019-03-19 京津冀联创药物研究（北京）有限公司 一种索拉非尼组合物及其制备方法
US11712418B2 (en) 2017-05-26 2023-08-01 Bruin Biosciences, Inc. Chemoembolization agents
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (fr) * 2018-09-07 2018-11-22 Alvogen Malta Operations (Row) Ltd Forme galénique solide contenant du tosylate de sorafénib
WO2020093011A1 (fr) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
WO2021026046A1 (fr) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Traitement de cancers canins
KR20230017165A (ko) 2020-03-06 2023-02-03 인사이트 코포레이션 Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125359A (en) * 1964-03-17 Push-pull breakaway coupling
NL121140C (fr) * 1961-11-08
AU594098B2 (en) 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
EP0841910A4 (fr) 1995-07-25 2006-09-13 Smithkline Beecham Corp INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE
BR9708735A (pt) 1996-04-23 1999-08-03 Vertex Pharma Derivados de uréia como inibidores da enzina impdh
DE1019040T1 (de) 1997-05-23 2001-02-08 Bayer Corp., West Haven Hemmung von p38 kinase aktivität durch arylharnstoff
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
DE69839639D1 (en) 1997-05-23 2008-08-07 Bayer Pharmaceuticals Corp Raf kinase hemmer
WO1999032455A1 (fr) 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase a l'aide d'urees heterocycliques aryle et heteroaryle substituees
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
WO1999032111A1 (fr) 1997-12-22 1999-07-01 Bayer Corporation Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques substituees
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
TR200002616T2 (tr) 1997-12-22 2000-11-21 Bayer Corporation Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
WO1999032110A1 (fr) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION DE L'ACTIVITE DE p38 KINASE AU MOYEN D'UREES HETEROCYCLIQUES ARYLE ET HETEROARYLE SUBSTITUEES
EP1616865A1 (fr) 1997-12-22 2006-01-18 Bayer Pharmaceuticals Corporation INHIBITION DE LA KINASE p38 PAR DES DIPHENYL-UREES SYMETRIQUES ET DISSYMETRIQUES
HUP0101704A3 (en) 1997-12-22 2002-12-28 Bayer Corp Pittsburgh Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20030087849A1 (en) 2001-07-03 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of HKR1 expression
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
CN1183114C (zh) 1999-01-22 2005-01-05 麒麟麦酒株式会社 喹啉衍生物及喹唑啉衍生物
DE60120710T2 (de) * 2000-08-18 2007-06-14 Pharmacia Corp. Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UY27225A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20030207914A1 (en) 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1379505B1 (fr) 2001-04-20 2007-02-28 Bayer Pharmaceuticals Corporation Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl
CA2468463C (fr) * 2001-12-03 2013-06-18 Bayer Pharmaceuticals Corporation Composes de type uree aryle combines a d'autres agents cytostatiques ou cytotoxiques et servant a traiter des cancers humains
JP2005526008A (ja) 2001-12-04 2005-09-02 オニックス ファーマシューティカルズ，インコーポレイティド 癌を処置するためのｒａｆ−ｍｅｋ−ｅｒｋ経路インヒビター
US20080108672A1 (en) 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP1474393A1 (fr) 2002-02-11 2004-11-10 Bayer Pharmaceuticals Corporation Aryle-urees en tant qu'inhibiteurs de kinase
US20040023961A1 (en) 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AU2003243318A1 (en) 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ATE489379T1 (de) 2003-02-28 2010-12-15 Bayer Healthcare Llc 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
WO2004078128A2 (fr) 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Derives de pyridine substitues utilises pour traiter des cancers et d'autres troubles
CA2516931C (fr) 2003-02-28 2014-09-09 Bayer Pharmaceuticals Corporation Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles
US6896863B2 (en) 2003-04-01 2005-05-24 E. I. Du Pont De Nemours And Company Sodium cyanide process
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
US20060234931A1 (en) * 2003-07-17 2006-10-19 Biggs William H Iii Treatment of diseases with kinase inhibitors
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
EA200600495A1 (ru) 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
US7552093B2 (en) * 2003-12-04 2009-06-23 Black Duck Software, Inc. Resolving license dependencies for aggregations of legally-protectable content
JP2007515957A (ja) 2003-12-12 2007-06-21 バイエル・フアーマシユーチカルズ・コーポレーシヨン ガンの予示及び予後ならびにガン治療の監視のための方法
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
JP2008503560A (ja) 2004-06-22 2008-02-07 ファイザー・プロダクツ・インク ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ES2306216T3 (es) 2004-08-27 2008-11-01 Bayer Pharmaceuticals Corporation Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer.
CN101052619B (zh) 2004-09-29 2012-02-22 拜耳先灵制药股份公司 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法
BRPI0515946A (pt) 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
DK1868579T3 (da) 2005-03-07 2011-01-10 Bayer Schering Pharma Ag Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
MX2007014920A (es) 2005-05-27 2008-04-09 Bayer Healthcare Ag Politerapia que comprende diarilureas para el tratamiento de enfermedades.
RU2007148266A (ru) 2005-05-27 2009-07-10 Байер ХельсКер АГ (DE) Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака
EP1937837A2 (fr) 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methodes et trousses pour la prediction du succes therapeutique, de la survie sans recidive et globale dans des therapies du cancer
RU2395090C2 (ru) 2005-10-21 2010-07-20 БАЙЕР ХелсКер ЛЛСи Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний
CA2627875A1 (fr) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Diaryle-urees et combinaisons
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP1954272A2 (fr) 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Traitement du cancer au moyen de sorafenib
JP2009515166A (ja) 2005-11-02 2009-04-09 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
JP2009515167A (ja) 2005-11-02 2009-04-09 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
CA2628847A1 (fr) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryle-urees permettant de traiter l'hypertension pulmonaire
RU2008123406A (ru) 2005-11-14 2009-12-27 Байер Хелскеа эЛэЛСи (US) Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента
WO2007059155A1 (fr) 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Traitement de cancers a resistance a des agents chimiotherapeutiques
EP1957069A2 (fr) 2005-11-14 2008-08-20 Bayer Healthcare, LLC Traitement de cancers a resistance acquise a des inhibiteurs de kit
EP2044053A2 (fr) 2005-12-01 2009-04-08 Bayer Healthcare, LLC Composes de l'uree utilises dans le traitement du cancer
US20090227637A1 (en) 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
US8101773B2 (en) 2006-12-20 2012-01-24 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer
CA2675980C (fr) 2007-01-19 2016-06-21 Bayer Healthcare Llc Utilisation de dast dans le traitement des cancers a resistance acquise a des inhibiteurs de kit
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
EP2559431A1 (fr) 2011-08-17 2013-02-20 Ratiopharm GmbH Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide

Also Published As

Publication number Publication date
HK1209620A1 (en) 2016-04-08
IL185517A (en) 2016-05-31
HN2006009702A (es) 2010-06-08
DE602006017188D1 (de) 2010-11-11
WO2006094626A1 (fr) 2006-09-14
JP2008531741A (ja) 2008-08-14
BRPI0608840B1 (pt) 2020-04-14
US20180036249A1 (en) 2018-02-08
AU2006222365B2 (en) 2011-07-14
RU2007136896A (ru) 2009-04-20
TWI324928B (en) 2010-05-21
CR9348A (es) 2008-02-13
HK1118019A1 (zh) 2009-01-30
MX2007010856A (es) 2007-11-12
JP5304241B2 (ja) 2013-10-02
CY1111065T1 (el) 2015-06-11
NZ561178A (en) 2010-11-26
HRP20100674T1 (hr) 2011-01-31
SI1868579T1 (sl) 2011-02-28
CN101132779A (zh) 2008-02-27
CU23821A3 (es) 2012-06-21
IL185517A0 (en) 2008-01-06
SG160364A1 (en) 2010-04-29
ATE482693T1 (de) 2010-10-15
AR054234A1 (es) 2007-06-13
ZA200707638B (en) 2009-08-26
AU2006222365A1 (en) 2006-09-14
TW200700093A (en) 2007-01-01
UA93673C2 (ru) 2011-03-10
RU2420283C2 (ru) 2011-06-10
MY162319A (en) 2017-05-31
CN101132779B (zh) 2016-03-16
US9737488B2 (en) 2017-08-22
UY29410A1 (es) 2006-10-31
CA2601955A1 (fr) 2006-09-14
KR20070111513A (ko) 2007-11-21
CU20070203A7 (es) 2010-01-22
CN104688697A (zh) 2015-06-10
EP1868579A1 (fr) 2007-12-26
BRPI0608840B8 (pt) 2021-05-25
NO343834B1 (no) 2019-06-17
PT1868579E (pt) 2010-12-03
US20080242707A1 (en) 2008-10-02
CA2601955C (fr) 2012-07-10
PE20061345A1 (es) 2007-01-28
KR101335932B1 (ko) 2013-12-04
NO20075042L (no) 2007-10-05
TNSN07341A1 (en) 2008-12-31
BRPI0608840A2 (pt) 2010-02-02
GT200600096A (es) 2007-01-12
ES2351612T3 (es) 2011-02-08
PL1868579T3 (pl) 2011-03-31
DOP2006000057A (es) 2006-09-30
DK1868579T3 (da) 2011-01-10
EP1868579B1 (fr) 2010-09-29

Similar Documents

Publication Publication Date Title
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA47399B1 (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA34308B1 (fr) Triazolopyridines substituées
CA2407100A1 (fr) 1-aroyle-piperidinyle benzamidines
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
MY145074A (en) Thiazolidin-4-one derivatives
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale